These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34708270)

  • 21. Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies.
    Levintow SN; Orroth KK; Breskin A; Park AS; Flores-Arredondo JH; Dluzniewski P; Navar AM; Sørensen HT; Brookhart MA
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):383-392. PubMed ID: 34894377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
    Davis LE; Pogge EK
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
    Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD
    Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies.
    Kumar SS; Haridoss M; Venkataraman K; Bagepally BS
    Front Pharmacol; 2022; 13():1090361. PubMed ID: 36582538
    [No Abstract]   [Full Text] [Related]  

  • 28. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression.
    Hirsh Raccah B; Yanovsky A; Treves N; Rotshild V; Renoux C; Danenberg H; Eliaz R; Matok I
    Int J Cardiol; 2021 Jul; 335():7-14. PubMed ID: 33892045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness evaluation of the use of PCSK9 inhibitors.
    Civeira F; Pedro-Botet J
    Endocrinol Diabetes Nutr (Engl Ed); 2021; 68(6):369-371. PubMed ID: 34742469
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
    Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
    J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.
    Marquina C; Zomer E; Vargas-Torres S; Zoungas S; Ofori-Asenso R; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Oct; 38(10):1095-1113. PubMed ID: 32583316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials.
    Chiu SW; Pratt CM; Feinn R; Chatterjee S
    J Cardiovasc Pharmacol Ther; 2020 Sep; 25(5):409-417. PubMed ID: 32419478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.
    Muntner P; Ghazi L; Jones J; Dhalwani N; Poudel B; Wen Y; Chen L; Wang Z; Bittner V; Kalich B; Farkouh ME; Woodward M; Colantonio LD; Rosenson RS
    Adv Ther; 2024 Jun; 41(6):2399-2413. PubMed ID: 38691317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective.
    Liang Z; Chen Q; Yang F; Yan X; Zhang X; Chen X; Fang F; Zhao Q
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):775-785. PubMed ID: 33090294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of PCSK9 Inhibitors in Practice.
    Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
    Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors.
    Choi HD; Kim JH
    Cardiovasc Ther; 2023; 2023():7362551. PubMed ID: 36704607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.
    Atia A; Aboeldahab H; Wageeh A; Elneny M; Elmallahy M; Elawfi B; Aboelkhier MM; Elrosasy A; Abdelwahab MM; Sayed S; Abdelaziz A
    Am J Cardiovasc Drugs; 2024 Jan; 24(1):83-102. PubMed ID: 38241002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCSK9 Inhibitors Show Value for Patients and the US Health Care System.
    Cheng WH; Gaudette É; Goldman DP
    Value Health; 2017 Dec; 20(10):1270-1278. PubMed ID: 29241886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.